Elvina Almuradova, Ambassador at European School of Oncology, shared a post on X:
“The recent FDA approval of larotrectinib reminds us of something critical:
NTRK fusions can occur across many tumor types, yet we often don’t test for them.
By missing the fusion, we miss the opportunity and that makes things harder than they need to be!”
More posts featuring Elvina Almuradova.